Wuxi Taxus Pharmaceutical Co Ltd.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of apalutamide tablets (specification: 60 mg) owned by Wuxi Taxus Pharmaceutical Co., Ltd. and produced by Shanghai Chuangnuo Pharmaceutical Co., Ltd. and apalutamide tablets (trade name: Erleada®/Ansenke®, specification: 60 mg) licensed by Janssen-Cilag International NV in healthy Chinese male subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test and reference preparations of apalutamide tablets after a single oral dose in healthy Chinese male subjects.